Role of tolcapone in the treatment of Parkinson’s disease

References

• De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol.5, 525–535 (2006).
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Biochemical aspects of Parkinson’s disease. Neurology51, S2–S9 (1998).
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron39, 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Block G, Liss C, Reines S et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. Eur. Neurol.37, 23–27 (1997).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16, 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben–Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited – clinical features, natural history and mortality. Mov. Disord.13(6), 885–894 (1998).
   PubMed Web of Science ®Google Scholar
• Chuang C, Waters CH. Initial therapy of Parkinson’s disease. In: Office Practice of Neurology (2nd Edition). Samuels M, Feske S (Eds). Churchill Livingstone, PA, USA 743–748 (2003).
   Google Scholar
• Pahwa P, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Guay DR. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson’s disease. Pharmacotherapy19, 6–20 (1999).
   PubMedGoogle Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs59, 1233–1250 (2000).
   PubMed Web of Science ®Google Scholar
• Mannisto PT. Clinical potential of catechol-O-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson’s disease. CNS Drugs1, 172–179 (1994).
   PubMed Web of Science ®Google Scholar
• Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen. Pharmacol.25, 813–824 (1994).
   PubMedGoogle Scholar
• Mannisto PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol. Toxicol.66, 317–323 (1990).
   PubMedGoogle Scholar
• Zurcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40–7592 in the periphery and in the brain. Adv. Neurol.60, 641–647 (1993).
   PubMedGoogle Scholar
• Doudet DJ, Chan GL, Holden JE et al. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. Eur. J. Pharmacol.334, 31–38 (1997).
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brools DJ. 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse43, 201–207 (2002).
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Jorga K, Schmitt M et al. Integrated pharmacokinetic and pharmacodynamics of the novel catechol-O-methyl-transferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther.57, 508–517 (1995).
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Jorga K, Zurcher G et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol.50, 47–55 (1995).
   Google Scholar
• Dingemanse J, Jorga K, Zurcher G et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Clin. Pharmacol.40, 253–262 (1995).
   PubMed Web of Science ®Google Scholar
• Limousin P, Pollak P, Pfefen JP et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin. Neuropharmacol.18, 258–265 (1995).
   PubMedGoogle Scholar
• Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin. Neuropharmacol.18, 333–337 (1995).
   PubMed Web of Science ®Google Scholar
• Sedek G, Jorga K, Schmitt M et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol.20, 531–541 (1997).
   PubMed Web of Science ®Google Scholar
• Jorga KM, Sedek G, Fotteler B et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther.62, 300–310 (1997).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yokochi M, Kuno S et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson’s disease. J. Neural. Transm.104, 229–236 (1997).
   PubMedGoogle Scholar
• Napolitano A, Del Dotto P, Petrozzi L et al. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson’s disease. Clin. Neuropharmacol.22, 24–29 (1999).
   PubMed Web of Science ®Google Scholar
• Muller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H. Tolcapone increases maximum concentration of levodopa. J. Neural Transm.107, 113–119 (2000).
   PubMed Web of Science ®Google Scholar
• Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin. Pharmacokinet.40, 383–393 (2001).
   PubMed Web of Science ®Google Scholar
• Jorga KM, Kroodsma JM, Fotteler B et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin. Pharmacol. Ther.63, 646–654 (1998).
   PubMed Web of Science ®Google Scholar
• Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin. Neuropharmacol.21, S9–S16 (1998).
   Google Scholar
• Kuhn W, Roebroeck R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur. Neurol.40, 225–227 (1998).
   PubMed Web of Science ®Google Scholar
• Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol. Scand.108, 66–67 (2003).
   PubMed Web of Science ®Google Scholar
• Muller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson’s disease patients. Eur. J. Clin. Pharmacol.62, 447–450 (2006).
   PubMedGoogle Scholar
• Lamberti P, Zoccolella S, Iliceto G et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patients. Mov. Disord.20, 69–72 (2005).
   PubMed Web of Science ®Google Scholar
• Ostrem JL, Kang JA, Subramanian I et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology64, 1482 (2005).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Espay AJ, Zadikoff C et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled trial. Neurology66, 1941–1943 (2006).
   PubMed Web of Science ®Google Scholar
• Baas H, Beiske AG, Ghika J et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry63, 421–428 (1997).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Martin W, Saint-Hilaire M-H et al. Tolcapone improves motor function in parkinsonian patients with the ‘wearing-off’ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology49, 1066–1071 (1997).
   PubMed Web of Science ®Google Scholar
• Waters CH, Kurth M, Bailey P et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology49, 665–671 (1997).
   PubMed Web of Science ®Google Scholar
• Dupont E, Burginder JM, Findley LJ et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov. Disord.12, 928–934 (1997).
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Bailey P, Pourchar E et al. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. Neuropharmacol.24, 214–220 (2001).
   PubMedGoogle Scholar
• Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord.14, 38–44 (1999).
   PubMed Web of Science ®Google Scholar
• Koller W, Lees A, Doder M, Hely M; Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov. Disord.16, 858–866 (2001).
   PubMed Web of Science ®Google Scholar
• Adler CH, Singer C, O’Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch. Neurol.55, 1089–1095 (1998).
   PubMedGoogle Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann. Neurol.42, 747–755 (1997).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Larsen JP, Siden A et al. Entacapone enhances the response to levodopa in patients with PD with motor fluctuations. Neurology51, 1309–1314 (1998).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Feustel PJ et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin. Neuropharmacol.5, 295–299 (2001).
   Google Scholar
• Onofrj M, Thomas A, Iacono D et al. Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur. Neurol.46, 11–16 (2001).
   PubMed Web of Science ®Google Scholar
• The Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov. Disord.22(1), 14–19 (2007).
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A et al. Tolcapone and fulminant hepatitis. Lancet352, 958 (1998).
   PubMed Web of Science ®Google Scholar
• New Warnings for Parkinson’s Drug Tasmar. US FDA, Rockville, MD, USA, Talk paper T98–T81 (1998).
   Google Scholar
• Olanow CW and the Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch. Neurol.57, 263–267 (2000).
   PubMed Web of Science ®Google Scholar
• Acuna G, Foernzler D, Leong D et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J.2, 327–334 (2002).
   PubMedGoogle Scholar
• Martignoni M, Cosentino M, Ferrari G et al. Two patients with COMT inhibitor–induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology65, 1820–1822 (2005).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology63, 886–891 (2004).
   PubMed Web of Science ®Google Scholar
• Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N. Engl. J. Med.346, 476–483 (2002).
   PubMed Web of Science ®Google Scholar
• Sasaki T, Watanabe M, Nagai Y et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke33, 1493–1496 (2002).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Lonn E, Genest J et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med.131, 363–375 (1999).
   PubMed Web of Science ®Google Scholar
• Bottiglieri T, Laundy M, Crellin R et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry69, 228–232 (2000).
   PubMed Web of Science ®Google Scholar
• Lew MF. Tolcapone and the prevention of depression in patients with early-stage Parkinson’s disease initiating levodopa. Presented at: 10th International Congress of Parkinson’s Disease and Movement Disorders. Kyoto, Japan, 28 October–2 November 2006 (Abstract P1187).
   Google Scholar